Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Consolidation and reconsolidation are impaired by oral propranolol administered before but not after memory (re)activation in humans.

Thomas É, Saumier D, Pitman RK, Tremblay J, Brunet A.

Neurobiol Learn Mem. 2017 Jul;142(Pt A):118-125. doi: 10.1016/j.nlm.2016.12.010. Epub 2016 Dec 18.

PMID:
28003127
2.

Propranolol's impact on cognitive performance in post-traumatic stress disorder.

Mahabir M, Ashbaugh AR, Saumier D, Tremblay J.

J Affect Disord. 2016 Mar 1;192:98-103. doi: 10.1016/j.jad.2015.11.051. Epub 2015 Dec 8.

PMID:
26707354
3.

Reactivating addiction-related memories under propranolol to reduce craving: A pilot randomized controlled trial.

Lonergan M, Saumier D, Tremblay J, Kieffer B, Brown TG, Brunet A.

J Behav Ther Exp Psychiatry. 2016 Mar;50:245-9. doi: 10.1016/j.jbtep.2015.09.012. Epub 2015 Oct 22.

PMID:
26454715
4.

Trauma reactivation plus propranolol is associated with durably low physiological responding during subsequent script-driven traumatic imagery.

Brunet A, Thomas É, Saumier D, Ashbaugh AR, Azzoug A, Pitman RK, Orr SP, Tremblay J.

Can J Psychiatry. 2014 Apr;59(4):228-32.

5.

Peritraumatic distress and the course of posttraumatic stress disorder symptoms: a meta-analysis.

Thomas É, Saumier D, Brunet A.

Can J Psychiatry. 2012 Feb;57(2):122-9. Review.

PMID:
22340152
6.

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J.

Arch Med Sci. 2011 Feb;7(1):102-11. doi: 10.5114/aoms.2011.20612. Epub 2011 Mar 8.

7.

Does reconsolidation occur in humans: a reply.

Brunet A, Ashbaugh AR, Saumier D, Nelson M, Pitman RK, Tremblay J, Roullet P, Birmes P.

Front Behav Neurosci. 2011 Oct 31;5:74. doi: 10.3389/fnbeh.2011.00074. eCollection 2011. No abstract available.

8.

Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models.

Shen KK, Fripp J, Mériaudeau F, Chételat G, Salvado O, Bourgeat P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2155-66. doi: 10.1016/j.neuroimage.2011.10.014. Epub 2011 Oct 14.

PMID:
22037419
9.

Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data.

Cho Y, Seong JK, Jeong Y, Shin SY; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2217-30. doi: 10.1016/j.neuroimage.2011.09.085. Epub 2011 Oct 8.

PMID:
22008371
10.

BEaST: brain extraction based on nonlocal segmentation technique.

Eskildsen SF, Coupé P, Fonov V, Manjón JV, Leung KK, Guizard N, Wassef SN, Østergaard LR, Collins DL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2012 Feb 1;59(3):2362-73. doi: 10.1016/j.neuroimage.2011.09.012. Epub 2011 Sep 16.

11.

Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis.

McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Radiology. 2011 Jun;259(3):834-43. doi: 10.1148/radiol.11101975. Epub 2011 Apr 6.

12.

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.

Tosun D, Schuff N, Mathis CA, Jagust W, Weiner MW; Alzheimer's Disease NeuroImaging Initiative.

Brain. 2011 Apr;134(Pt 4):1077-88. doi: 10.1093/brain/awr044. Epub 2011 Mar 22.

13.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative, Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

14.

Biomarkers for Alzheimer's disease therapeutic trials.

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B; Oxford Task Force Group.

Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2. Review.

PMID:
21130138
15.

Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.

Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2010 Nov;67(11):1370-8. doi: 10.1001/archneurol.2010.284.

16.
17.

Scales as outcome measures for Alzheimer's disease.

Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y.

Alzheimers Dement. 2009 Jul;5(4):324-39. doi: 10.1016/j.jalz.2009.05.667.

PMID:
19560103
18.

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J.

J Nutr Health Aging. 2009 Jun;13(6):550-7. Erratum in: J Nutr Health Aging. 2010 Jan;14(1):80.

PMID:
19536424
19.

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.

Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J.

J Nutr Health Aging. 2009 Apr;13(4):370-2. No abstract available.

PMID:
19300884
20.

Cognitive neuroscience studies of semantic memory in Alzheimer's disease.

Chertkow H, Whatmough C, Saumier D, Duong A.

Prog Brain Res. 2008;169:393-407. doi: 10.1016/S0079-6123(07)00025-8. Review.

PMID:
18394489

Supplemental Content

Loading ...
Support Center